Earnings ·
Ocular Therapeutix reported second quarter 2026 financial results with total net revenue of $13.5 million and a net…
OCULOcular Therapeutix, Inc
Ocular Therapeutix reported second quarter 2026 financial results with total net revenue of $13.5 million and a net loss of $(78.8) million, or $(0.35) per share. The company holds $598.6 million in cash as of June 30, 2026, providing runway into 2028. Key business highlights include plans to submit a New Drug Application for AXPAXLI in wet AMD by Q4 2026 following positive FDA alignment. The company also announced amendments to the SOL-R and HELIOS-3 clinical trial protocols to optimize development pathways.